Hot Pursuit     04-Mar-24
Biocon gains after subsidiary secures 'Yesafili' entry into Canadian market
Biocon added 1.16% to Rs 280.05 after Biocon Biologics announced the signing of a settlement agreement with Bayer and Regeneron Pharma for introduction of Yesafili, a proposed biosimilar to EYLEA (aflibercept) injection, into the Canadian market.

Under the terms of the agreement, Biocon Biologics has secured a launch date for YESAFILI 2 mg NDS for vials and prefilled syringes (yet to be filed), set no later than 1 July 2025.

In March 2023, Health Canada had granted tentative approval for YESAFILI 2 mg vials, subject to resolution of any patent issues.

The settlement resolves multiple parallel patent infringement proceedings in the Federal Court of Canada involving six patents, and associated judicial review proceedings, under Canada’s Patented Medicines (Notice of Compliance) Regulations addressing pre-entry pharmaceutical patent litigation.

Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development.

The company had reported consolidated net profit of Rs 660 crore in Q3 FY24 as compared with net loss of Rs 41.8 crore posted in Q3 FY23. Revenue from operations jumped 34.43% year on year (YoY) to Rs 3,953.7 crore in the quarter ended 31 December 2023.

Previous News
  Biocon gets US FDA nod for fungal infection drug
 ( Hot Pursuit - 04-Jun-24   11:18 )
  Biocon gets nod from SAHPRA for Tacrolimus capsules
 ( Hot Pursuit - 20-Apr-24   15:36 )
  Board of Biocon to consider NCD issuance and investment in Biocon Biologics
 ( Corporate News - 24-Apr-23   09:50 )
  Board of Biocon recommends final dividend
 ( Corporate News - 16-May-24   17:54 )
  Biocon edges higher after obtaining UK MHRA nod for diabetes drug Liraglutide
 ( Hot Pursuit - 28-Mar-24   10:06 )
  Biocon’s Andhra Pradesh facility gets 3 USFDA observations
 ( Hot Pursuit - 15-Jun-24   16:32 )
  Biocon wins EcoVadis' Silver medal for its sustainability initiatives
 ( Corporate News - 03-Apr-23   13:29 )
  Biocon Ltd drops for fifth straight session
 ( Hot Pursuit - 23-Feb-23   13:35 )
  Biocon redeems commercial papers worth Rs 2,250 crore
 ( Hot Pursuit - 23-Feb-23   11:50 )
  Mahindra Lifespace Developers Ltd leads losers in 'A' group
 ( Hot Pursuit - 28-Jul-22   15:00 )
  Volumes jump at Akzo Nobel India Ltd counter
 ( Hot Pursuit - 10-Feb-23   11:00 )
Other Stories
  JSW Energy PAT soars 80% YoY to Rs 522 crore in Q1 FY25
  20-Jul-24   17:15
  Yes Bank Q1 PAT climbs 47% YoY to Rs 502 crore
  20-Jul-24   16:46
  Patanjali Foods Q1 PAT soars 3-fold to Rs 263 cr
  20-Jul-24   16:08
  Nippon Life Q1 PAT surges 40% YoY to Rs 332 cr
  20-Jul-24   15:44
  HDFC Bank Q1 PAT grows 35% YoY to Rs 16,175 crore
  20-Jul-24   15:31
  Kotak Mahindra Bank Q1 PAT zooms 81% YoY to Rs 6,250 cr
  20-Jul-24   15:13
  JSW Steel Q1 PAT drops 64% YoY to Rs 867 crore
  20-Jul-24   13:39
  ICICI Lombard Q1 PAT climbs 49% YoY to Rs 580 cr
  20-Jul-24   12:14
  Oberoi Realty Q1 PAT soars 82% YoY to Rs 584 cr
  20-Jul-24   11:16
  RIL PAT slides 4% YoY to Rs 17,448 crore in Q1 FY25
  20-Jul-24   10:33
Back Top